INTRODUCTION
This analysis examines the current position and future outlook for Human
Genome Science (HGS) in the biotechnology sector. It encompasses company
strategy, comparative portfolio and pipeline analysis and assessment of
financial performance, providing 1, 3 and 6 year sales forecasts for key drugs.
KEY REASONS TO BUY THIS REPORT
- Assess HGS's plans to develop an independent business model following the
creation of an integrated platform of genomics-based vertical technologies
- Evaluate to what extent the commercialization potential of the newly
acquired albumin fusion technology is threatened by questionable IPR status
- Understand the threats posed by HGS's lack of pipeline maturity, the
discontinuation of Mirostipen and the failure of Repifermin in phase II
- Benchmark HGS's performance with leading rivals in the biotechnology
sector
View Cart
